Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US
Shots:
- Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC
- The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing advanced/m-BC
- Fulvestrant Injection is a prescription therapy used to treat multiple forms of advanced breast cancer and has generated ~$550M in 12mos. ending Jun 30- 2019
Click here to read full press release/ article | Ref: Mylan | Image: WSJ
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
